(MENAFN- ABN Newswire)
Half Yearly Report and Accounts Brisbane, Feb 22, 2018 AEST (ABN Newswire) - Anatara Lifesciences () today released its Appendix 4D financial report for the half year ending 31st December 2017.
Highlights from the period include:
- Global animal health company, Zoetis Inc, exercising its option to negotiate a commercial agreement for the worldwide development, distribution and marketing of Detach(R).
- Establishing an experienced veterinary team focused on launching Detach(R) into the anti-diarrhoeal therapeutic pig market.
- Developing a proprietary dosing device for the optimal delivery of Detach(R) by pig farmers
- Presenting at the Australasian Pig Science Association (APSA) Conference - highlighting the comparable efficacy of Detach(R) to in-feed Zinc Oxide
- Increasing focus on human opportunities through the development of proprietary products for the management of diarrhoea associated with gastrointestinal disorders
To view the full report, please visit:
About Anatara Lifesciences Ltd
() is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(R) is a natural plant based product that aids in the control of diarrhoea and will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.
MENAFN2102201801110000ID1096495451
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.